CA3212016A1 - Treatment of copper disorders - Google Patents
Treatment of copper disorders Download PDFInfo
- Publication number
- CA3212016A1 CA3212016A1 CA3212016A CA3212016A CA3212016A1 CA 3212016 A1 CA3212016 A1 CA 3212016A1 CA 3212016 A CA3212016 A CA 3212016A CA 3212016 A CA3212016 A CA 3212016A CA 3212016 A1 CA3212016 A1 CA 3212016A1
- Authority
- CA
- Canada
- Prior art keywords
- copper
- triethylenetetramine disuccinate
- triethylenetetramine
- dose
- article
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4525—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/04—Chelating agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Conductive Materials (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163157539P | 2021-03-05 | 2021-03-05 | |
| US63/157,539 | 2021-03-05 | ||
| PCT/US2022/019025 WO2022187709A1 (en) | 2021-03-05 | 2022-03-04 | Treatment of copper disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3212016A1 true CA3212016A1 (en) | 2022-09-09 |
Family
ID=83115853
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3212016A Pending CA3212016A1 (en) | 2021-03-05 | 2022-03-04 | Treatment of copper disorders |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20220280451A1 (https=) |
| EP (1) | EP4301350A4 (https=) |
| JP (1) | JP2024509193A (https=) |
| CN (1) | CN117157064A (https=) |
| AU (1) | AU2022231038A1 (https=) |
| CA (1) | CA3212016A1 (https=) |
| WO (1) | WO2022187709A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2023255339A1 (en) * | 2022-04-19 | 2024-12-05 | Sasha A. PHILBERT | Treatment of brain copper disorders |
| CN118987254A (zh) * | 2024-08-15 | 2024-11-22 | 沈阳药科大学 | 一种基于双金属纳米点-溶瘤病毒静脉递送系统及其制备方法和应用 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2875522A1 (en) * | 2002-08-20 | 2004-03-04 | Philera New Zealand Limited | Dosage forms and related therapies |
| PT1778618E (pt) * | 2004-07-19 | 2014-03-04 | Philera New Zealand Ltd | Síntese de trietilenotetraminas |
| WO2006104396A1 (en) * | 2005-03-26 | 2006-10-05 | Protemix Corporation Limited | Pre-complexed copper antagonist compositions |
| CA3018698A1 (en) * | 2005-11-09 | 2007-05-18 | Philera New Zealand Limited | Treatment of mitochondria-related diseases and improvement of age-related metabolic deficits |
| US20090093542A1 (en) * | 2007-10-04 | 2009-04-09 | Cooper Garth J S | Copper antagonist compositions |
| WO2017049529A1 (en) * | 2015-09-24 | 2017-03-30 | Innolife Co., Ltd. | A pharmaceutical composition comprising a copper chelating tetramine and the use thereof |
| WO2017213524A1 (en) * | 2016-06-10 | 2017-12-14 | Garth Cooper | Treatment of neurodegenerative disorders |
| CA3143523A1 (en) * | 2019-06-17 | 2020-12-24 | Philera New Zealand Ltd. | Combination treatments for central nervous system disorders |
-
2022
- 2022-03-04 AU AU2022231038A patent/AU2022231038A1/en active Pending
- 2022-03-04 WO PCT/US2022/019025 patent/WO2022187709A1/en not_active Ceased
- 2022-03-04 US US17/687,525 patent/US20220280451A1/en not_active Abandoned
- 2022-03-04 EP EP22764195.8A patent/EP4301350A4/en active Pending
- 2022-03-04 CA CA3212016A patent/CA3212016A1/en active Pending
- 2022-03-04 CN CN202280025441.XA patent/CN117157064A/zh active Pending
- 2022-03-04 JP JP2023553584A patent/JP2024509193A/ja active Pending
-
2024
- 2024-08-09 US US18/799,881 patent/US20250114312A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20250114312A1 (en) | 2025-04-10 |
| EP4301350A4 (en) | 2025-04-09 |
| WO2022187709A1 (en) | 2022-09-09 |
| JP2024509193A (ja) | 2024-02-29 |
| US20220280451A1 (en) | 2022-09-08 |
| CN117157064A (zh) | 2023-12-01 |
| AU2022231038A1 (en) | 2023-09-21 |
| EP4301350A1 (en) | 2024-01-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20250114312A1 (en) | Treatment of copper disorders | |
| US9925158B2 (en) | Enterically coated cysteamine, cystamine and derivatives thereof | |
| ES3015717T3 (en) | A lysyl oxidase-like 2 inhibitor for use in treating myelofibrosis | |
| JP6067203B2 (ja) | ２−ヒドロキシ−５−フェニル安息香酸誘導体の処方および使用 | |
| KR20150132214A (ko) | 방사선 직장ｓ상결장염의 치료를 위한 조성물 및 방법 | |
| CN108289870A (zh) | 治疗特定患者群体的神经变性病症的方法 | |
| EP4445914A1 (en) | Pharmaceutical composition for treating tumors and use | |
| ES2659763T3 (es) | Composiciones y procedimientos para el tratamiento de obesidad y trastornos relacionados | |
| EP3242723B1 (en) | Use of hinokitiol for restoring physiology in iron-deficient organisms | |
| US20240130994A1 (en) | Ionic liquid formulations for treating diabetes | |
| US10231946B2 (en) | Methods of treating ischemic organ damage and other disorders | |
| Maduri et al. | Formulation of colchicine ointment for the treatment of acute gout | |
| CN113476432B (zh) | J147在制备治疗和/或预防色素增多性疾病的药物/化妆品的用途 | |
| EP3703670A1 (en) | Compositions and methods for treating septic cardiomyopathy | |
| CN118453879B (zh) | 恩杂鲁胺与铜离子载体联合在制备前列腺癌治疗药物中的应用 | |
| KR20260021653A (ko) | IgA 매개 질환의 치료 방법에 사용하기 위한 스파르센탄 | |
| Zhang et al. | Tetramethylpyrazine nitrone activates hypoxia-inducible | |
| RU2283112C1 (ru) | Противовоспалительное лекарственное средство | |
| TW202604485A (zh) | 患有肝損傷患者肝疾病之治療 | |
| TW202033199A (zh) | 化合物ａ與化合物ｂ聯合在製備治療痛風或高尿酸血症的藥物中的用途 | |
| CN120884569A (zh) | 二氢辣椒素在治疗血管钙化中的应用 | |
| HK1242186A1 (en) | Methods for maintaining or improving health, well-being and/or a physiological function in a subject | |
| HK1209329A1 (en) | Use of a composition comprising meglumine or a salt thereof for manufacturing a medicament for reducing or preventing the increase of triglyceride levels |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250228 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250228 Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250228 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260302 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260302 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260304 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - VOLUNTARY AMENDMENT Effective date: 20260304 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260305 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20260311 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-1-1-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20260311 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260317 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260317 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260317 |